Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lexaria Bioscience ( (LEXX) ) has provided an update.
Lexaria Bioscience has hired a contract research organization to run a new preclinical study, GLP-1-A26-1, that will test enhanced formulations of its DehydraTECH-semaglutide and DehydraTECH-CBD compositions in rats. The study aims to optimize pharmacokinetic performance, including brain biodistribution, as Lexaria seeks to strengthen its position in the fast-growing GLP-1 market for diabetes and weight-loss therapies.
The fully funded study will compare multiple novel formulations against existing DehydraTECH-based reference arms, using historical data to pinpoint superior drug delivery characteristics. A key objective is to develop alternatives or additives to Novo Nordisk’s SNAC excipient, which, if shown to be superior, could support new patents and create valuable proprietary IP that enhances Lexaria’s commercial appeal to pharmaceutical partners in the competitive GLP-1 space.
The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a drug delivery technology company that develops and licenses its patented DehydraTECH platform, designed to improve the oral absorption, bioavailability and side-effect profile of a range of active pharmaceutical ingredients. The company operates an in-house research laboratory, holds a broad global patent portfolio, and focuses on applications including GLP-1 drugs and cannabidiol in metabolic and neurological indications.
Average Trading Volume: 171,248
Technical Sentiment Signal: Sell
Current Market Cap: $24.39M
See more insights into LEXX stock on TipRanks’ Stock Analysis page.